5GRJ
 
 | | Crystal structure of human PD-L1 with monoclonal antibody avelumab | | Descriptor: | Programmed cell death 1 ligand 1, avelumab H chain, avelumab L chain | | Authors: | Liu, K, Tan, S, Chai, Y, Chen, D, Song, H, Zhang, C.W.-H, Shi, Y, Liu, J, Tan, W, Lyu, J, Gao, S, Yan, J, Qi, J, Gao, G.F. | | Deposit date: | 2016-08-11 | | Release date: | 2016-11-02 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (3.206 Å) | | Cite: | Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.
Cell Res., 27, 2017
|
|
5KSB
 | | T15-DQ8.5-glia-gamma1 complex | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, DQ8.5-glia-gamma1 peptide, ... | | Authors: | Petersen, J, Rossjohn, J, Reid, H.H. | | Deposit date: | 2016-07-08 | | Release date: | 2016-09-21 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Diverse T Cell Receptor Gene Usage in HLA-DQ8-Associated Celiac Disease Converges into a Consensus Binding Solution.
Structure, 24, 2016
|
|
5KS9
 | | Bel502-DQ8-glia-alpha1 complex | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Bel502 TCR alpha TRAV20*01, Bel502 TCR beta TRBV9*01, ... | | Authors: | Petersen, J, Rossjohn, J, Reid, H.H. | | Deposit date: | 2016-07-08 | | Release date: | 2016-09-21 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (2.55 Å) | | Cite: | Diverse T Cell Receptor Gene Usage in HLA-DQ8-Associated Celiac Disease Converges into a Consensus Binding Solution.
Structure, 24, 2016
|
|
5KSA
 | | Bel602-DQ8.5-glia-gamma1 complex | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Bel602 alpha TRAV20*01, Bel602 beta TRBV9*01, ... | | Authors: | Petersen, J, Rossjohn, J, Reid, H.H. | | Deposit date: | 2016-07-08 | | Release date: | 2016-09-21 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Diverse T Cell Receptor Gene Usage in HLA-DQ8-Associated Celiac Disease Converges into a Consensus Binding Solution.
Structure, 24, 2016
|
|
5GGS
 | | PD-1 in complex with pembrolizumab Fab | | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | | Authors: | Heo, Y.S. | | Deposit date: | 2016-06-16 | | Release date: | 2016-11-09 | | Last modified: | 2016-11-16 | | Method: | X-RAY DIFFRACTION (1.997 Å) | | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGT
 | | PD-L1 in complex with BMS-936559 Fab | | Descriptor: | IGK@ protein, IgG H chain, Programmed cell death 1 ligand 1 | | Authors: | Heo, Y.S. | | Deposit date: | 2016-06-16 | | Release date: | 2016-11-09 | | Last modified: | 2024-03-20 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGR
 | | PD-1 in complex with nivolumab Fab | | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | | Authors: | Heo, Y.S. | | Deposit date: | 2016-06-16 | | Release date: | 2016-11-09 | | Last modified: | 2016-11-16 | | Method: | X-RAY DIFFRACTION (3.3 Å) | | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGV
 | | CTLA-4 in complex with tremelimumab Fab | | Descriptor: | Cytotoxic T-lymphocyte protein 4, heavy chain, light chain | | Authors: | Heo, Y.S. | | Deposit date: | 2016-06-16 | | Release date: | 2016-11-09 | | Last modified: | 2016-11-16 | | Method: | X-RAY DIFFRACTION (1.998 Å) | | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5B8C
 | | High resolution structure of the human PD-1 in complex with pembrolizumab Fv | | Descriptor: | Pembrolizumab heavy chain variable region (PemVH), Pembrolizumab light chain variable region (PemVL), Programmed cell death protein 1 | | Authors: | Horita, S, Shimamura, T, Iwata, S, Nomura, N. | | Deposit date: | 2016-06-14 | | Release date: | 2016-10-26 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (2.146 Å) | | Cite: | High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
Sci Rep, 6, 2016
|
|
5L8J
 | |
5L8L
 | |
5L8K
 | |
5JXE
 | | Human PD-1 ectodomain complexed with Pembrolizumab Fab | | Descriptor: | Pembrolizumab Fab heavy chain, Pembrolizumab Fab light chain, Programmed cell death protein 1 | | Authors: | Na, Z, Bharath, S.R, Song, H. | | Deposit date: | 2016-05-13 | | Release date: | 2016-08-10 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.
Cell Res., 27, 2017
|
|
5JDS
 | |
5JDR
 | | Structure of PD-L1 | | Descriptor: | Programmed cell death 1 ligand 1 | | Authors: | Zhou, A, Wei, H. | | Deposit date: | 2016-04-17 | | Release date: | 2017-04-12 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.
Cell Discov, 3, 2017
|
|
5J8O
 | | Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | | Descriptor: | (2R)-1-({3-bromo-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl}methyl)piperidine-2-carboxylic acid, Programmed cell death 1 ligand 1 | | Authors: | Zak, K.M, Grudnik, P, Guzik, K, Zieba, B.J, Musielak, B, Doemling, P, Dubin, G, Holak, T.A. | | Deposit date: | 2016-04-08 | | Release date: | 2016-04-27 | | Last modified: | 2024-01-10 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Oncotarget, 7, 2016
|
|
5J89
 | | Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | | Descriptor: | 1,2-ETHANEDIOL, N-{2-[({2-methoxy-6-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]pyridin-3-yl}methyl)amino]ethyl}acetamide, Programmed cell death 1 ligand 1 | | Authors: | Zak, K.M, Grudnik, P, Guzik, K, Zieba, B.J, Musielak, B, Doemling, P, Dubin, G, Holak, T.A. | | Deposit date: | 2016-04-07 | | Release date: | 2016-04-27 | | Last modified: | 2024-01-10 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Oncotarget, 7, 2016
|
|
5J0B
 | | Structure of the immune receptor CD33 in complex with 6'-sialyllactose | | Descriptor: | 2-(2-METHOXYETHOXY)ETHANOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, Myeloid cell surface antigen CD33, ... | | Authors: | Dodd, R.B. | | Deposit date: | 2016-03-28 | | Release date: | 2017-04-05 | | Last modified: | 2024-01-10 | | Method: | X-RAY DIFFRACTION (2.48 Å) | | Cite: | STRUCTURE OF LIGAND BOUND CD33 RECEPTOR ASSOCIATED WITH ALZHEIMER'S DISEASE
To Be Published
|
|
5J06
 | | Structure of the immune receptor CD33 in complex with 3'-sialyllactose | | Descriptor: | 2-(2-METHOXYETHOXY)ETHANOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, Myeloid cell surface antigen CD33, ... | | Authors: | Dodd, R.B. | | Deposit date: | 2016-03-27 | | Release date: | 2017-04-05 | | Last modified: | 2024-01-10 | | Method: | X-RAY DIFFRACTION (2.66 Å) | | Cite: | STRUCTURE OF LIGAND BOUND CD33 RECEPTOR ASSOCIATED WITH ALZHEIMER'S DISEASE
To Be Published
|
|
5IUS
 | | Crystal structure of human PD-L1 in complex with high affinity PD-1 mutant | | Descriptor: | CHLORIDE ION, Programmed cell death 1 ligand 1, Programmed cell death protein 1 | | Authors: | Pascolutti, R, Sun, X, Kao, J, Maute, R, Ring, A.M, Bowman, G.R, Kruse, A.C. | | Deposit date: | 2016-03-18 | | Release date: | 2016-09-28 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (2.889 Å) | | Cite: | Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.
Structure, 24, 2016
|
|
5IR3
 | |
5IMK
 | | Nanobody targeting human Vsig4 in Spacegroup C2 | | Descriptor: | Nanobody, V-set and immunoglobulin domain-containing protein 4 | | Authors: | Wen, Y. | | Deposit date: | 2016-03-06 | | Release date: | 2017-01-11 | | Last modified: | 2017-07-05 | | Method: | X-RAY DIFFRACTION (1.227 Å) | | Cite: | Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity
Immunobiology, 222, 2017
|
|
5IMO
 | | Nanobody targeting mouse Vsig4 in Spacegroup P3221 | | Descriptor: | Nanobody, Protein Vsig4 | | Authors: | Wen, Y, Zheng, F. | | Deposit date: | 2016-03-06 | | Release date: | 2017-01-11 | | Last modified: | 2017-07-05 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity
Immunobiology, 222, 2017
|
|
5IMM
 | | Nanobody targeting mouse Vsig4 in Spacegroup P212121 | | Descriptor: | Nanobody, Protein Vsig4 | | Authors: | Wen, Y, Zheng, F. | | Deposit date: | 2016-03-06 | | Release date: | 2017-01-11 | | Last modified: | 2017-07-05 | | Method: | X-RAY DIFFRACTION (1.2 Å) | | Cite: | Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity
Immunobiology, 222, 2017
|
|
5IML
 | | Nanobody targeting human Vsig4 in Spacegroup P212121 | | Descriptor: | Nanobody, V-set and immunoglobulin domain-containing protein 4 | | Authors: | Wen, Y. | | Deposit date: | 2016-03-06 | | Release date: | 2017-01-11 | | Last modified: | 2017-07-05 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity
Immunobiology, 222, 2017
|
|
